Skip to main content

Peer Review reports

From: Patient-reported outcome (PRO) results from the AGITG DOCTOR trial: a randomised phase 2 trial of tailored neoadjuvant therapy for resectable oesophageal adenocarcinoma

Original Submission
28 Jul 2021 Submitted Original manuscript
10 Aug 2021 Author responded Author comments - Rebecca Mercieca-Bebber
Resubmission - Version 2
10 Aug 2021 Submitted Manuscript version 2
15 Sep 2021 Reviewed Reviewer Report
8 Oct 2021 Reviewed Reviewer Report
8 Oct 2021 Reviewed Reviewer Report
27 Nov 2021 Author responded Author comments - Rebecca Mercieca-Bebber
Resubmission - Version 3
27 Nov 2021 Submitted Manuscript version 3
16 Dec 2021 Reviewed Reviewer Report
24 Dec 2021 Reviewed Reviewer Report
10 Jan 2022 Author responded Author comments - Rebecca Mercieca-Bebber
Resubmission - Version 4
10 Jan 2022 Submitted Manuscript version 4
27 Jan 2022 Author responded Author comments - Rebecca Mercieca-Bebber
Resubmission - Version 5
27 Jan 2022 Submitted Manuscript version 5
2 Feb 2022 Author responded Author comments - Rebecca Mercieca-Bebber
Resubmission - Version 6
2 Feb 2022 Submitted Manuscript version 6
Publishing
7 Feb 2022 Editorially accepted
15 Mar 2022 Article published 10.1186/s12885-022-09270-4

You can find further information about peer review here.

Back to article page